Ongoing quality control analysis has revealed that the current clinical trial supplies of SCIB1, Scancell’s lead product investigated as a monotherapy for the treatment of melanoma, are no longer within the original specification and, as a consequence – and in discussion with the MHRA Clinical Trials Unit – the company has decided the material is no longer suitable for further use although no new side effects have been seen. Dosing will therefore be suspended with the curren
